Domain Therapeutics grants Alkermes a non-exclusive license for its G Protein-Coupled Receptor bioSensAll™ technology. Technology provides access to a new set of sensitive biosensors that will facilitate drug discovery.
Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G protein-coupled receptors (GPCRs), announces today the signing of a licensing agreement for its GPCR bioSensAll™ technology with Alkermes, a biopharmaceutical company that focuses on developing medicines for the treatment of central nervous system diseases. As per the agreement, Alkermes is entitled to use bioSensAll™ as part of its drug discovery efforts. No financial details have been disclosed.